NEU
data caveat$1.5BCF+
Neuren Pharmaceuticals
Biotech · Neurology
Trofinetide for Rett syndrome, partnered with Acadia
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$192.7M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$1.5B
Burn Rate
—
Dec 2025 4C
Shares Outstanding
127M
Pipeline Assets
2
Latest Insight(1)
20 Apr 2026buybackUpdate - Notification of buy-back - NEU
$0.2M·On-Market·15,800 shares
3M Price
NEU.ASX$12.140-33.0% 3M
Low $11.280High $18.130
Pipeline Assets (2)
NNZ-2591Phelan-McDermid / Angelman
Phase 2Trofinetide (DAYBUE)Rett syndrome
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
NNZ-2591
Phelan-McDermid / Angelman
Capital Raises & Buybacks
9 buybacks
Current shares outstanding: 127M
Buyback
Buyback Detail
2026-04-21on-market
Director Transactions
1 transactionLast 90dNet Buy
Buys1+1 vs prior
Sells0
Buy Value$152k
warningJoseph Basile bought 57d before "DAYBUE royalty payment" ($151,782)
$151,7822026-03-05
34d before · Results posted — An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
5.69%
arrow_drop_up+0.25% over 30 reports
Shares short
7.2M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
1 approved drug11 competitor trialsPhase 2+ · Non-ASX
Rett Syndrome11 active trials
5 Ph31 Ph2/32 Ph23 Ph1/PHASE2
Approved
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
15 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Bioorg Med Chem2026-03· Trofinetide
Biomedicines2026-03· Trofinetide
Sci Transl Med2026-03· Trofinetide
Dev Med Child Neurol2026-03· Trofinetide
Catalysts (7)· 3 upcoming · 4 past
DAYBUE royalty payment
UpcomingConfirmedremoveMed1 May 2026
NNZ-2591 Phase 2 Phelan-McDermid interim
UpcomingExpectedarrow_upwardHigh31 July 2026
SpeculativeremoveMed31 Oct 2027
4 past catalysts
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High98/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 7/7 quarters with positive operating cash flow
arrow_drop_up
Revenue growing — Customer receipts trending up
arrow_drop_up
Cash position improving — Cash balance growing
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(5)
1 activeClinicalTrials.gov ↗
Ph3RecruitingEnrollment stale · 161d
NNZ-2591Placebo
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Phelan-McDermid Syndrome
RandomizedQuadruple Blind3 Years – 12 Years
Primary endpoint Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score.